Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related CPHD
Analysts Give Healthcare Sector A Clean Bill Of Health
Cepheid Margin Expansion Unlikely To Morgan Stanley, Stays On Sidelines
Cepheid (CPHD) John L. Bishop on Q2 2016 Results - Earnings Call Transcript (Seeking Alpha)
Related ABT
Argus Says Abbott Laboratories Shares Favorably Valued Despite 'Heightened' M&A Risks
Focus On Abbott Labs Remains On Pending Deals
3 Free Options (Seeking Alpha)

Analysts at Piper Jaffray downgraded Cepheid (NASDAQ: CPHD) from “overweight” to “neutral.” Cepheid's shares closed at $34.09 yesterday. Cepheid's trailing-twelve-month ROE is -12.52%.

Analysts at Deutsche Bank downgraded Abbott Laboratories (NYSE: ABT) from “buy” to “hold.” Abbott's shares closed at $33.27 yesterday. Abbott's PEG ratio is 0.51.

Analysts at Goldman Sachs downgraded Wells Fargo & Company (NYSE: WFC) from “buy” to “neutral.” Wells Fargo's shares closed at $34.76 yesterday. Wells Fargo's trailing-twelve-month profit margin is 23.18%.

Raymond James downgraded First Solar (NASDAQ: FSLR) from “market perform” to “underperform.” First Solar's shares closed at $34.41 yesterday. First Solar's trailing-twelve-month ROA is 2.17%.

Latest Ratings for CPHD

DateFirmActionFromTo
Jul 2016JP MorganMaintainsNeutral
Jun 2016Morgan StanleyInitiates Coverage onEqual-weight
Apr 2016BTIG ResearchUpgradesNeutralBuy

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (CPHD + ABT)

View Comments and Join the Discussion!